

# CITATION REPORT

List of articles citing

**Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies**

**DOI: 10.1038/s41423-020-0458-z**

**Cellular and Molecular Immunology, 2020, 17, 621-630.**

**Source:** <https://exaly.com/paper-pdf/76699758/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
356	ACE2 enhance viral infection or viral infection aggravate the underlying diseases. <b>2020</b> , 18, 2100-2106		4
355	Geriatric Population During the COVID-19 Pandemic: Problems, Considerations, Exigencies, and Beyond. <b>2020</b> , 8, 574198		27
354	Severe acute respiratory syndrome coronavirus-2 natural animal reservoirs and experimental models: systematic review. <b>2021</b> , 31, e2196		17
353	Molecular Dynamics Reveals Complex Compensatory Effects of Ionic Strength on the Severe Acute Respiratory Syndrome Coronavirus 2 Spike/Human Angiotensin-Converting Enzyme 2 Interaction. <b>2020</b> , 11, 10446-10453		10
352	Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation. <b>2020</b> , 8,		10
351	Some Energy Issues for a Nanoscale Electrostatic Potential Well in Saline Solutions. <b>2020</b> , 8, 50		
350	Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. <b>2020</b> , 369, 1603-1607		434
349	Global scenario, public health concerns and mitigation strategies to counter current ongoing SARS-CoV-2 / COVID-19 pandemic. <b>2020</b> , 16, 3023-3033		4
348	Sex differences in severity and mortality from COVID-19: are males more vulnerable?. <b>2020</b> , 11, 53		109
347	CoronaVR: A Computational Resource and Analysis of Epitopes and Therapeutics for Severe Acute Respiratory Syndrome Coronavirus-2. <b>2020</b> , 11, 1858		13
346	Comparative molecular dynamics study of the receptor-binding domains in SARS-CoV-2 and SARS-CoV and the effects of mutations on the binding affinity. <b>2020</b> , 1-20		16
345	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. <b>2020</b> , 11, 610688		90
344	Traditional medicinal plants against replication, maturation and transmission targets of SARS-CoV-2: computational investigation. <b>2020</b> , 1-18		9
343	Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. <b>2020</b> , 11, 1441		320
342	COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. <b>2020</b> , 94,		63
341	SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. <b>2020</b> , 8,		29
340	Culinary spice bioactives as potential therapeutics against SARS-CoV-2: Computational investigation. <b>2021</b> , 128, 104102		16

339	Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. <b>2021</b> , 538, 192-203	93
338	Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. <b>2021</b> , 23, 101-110	11
337	Development of a nano-luciferase based assay to measure the binding of SARS-CoV-2 spike receptor binding domain to ACE-2. <b>2021</b> , 534, 485-490	6
336	Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. <b>2021</b> , 7,	132
335	Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. <i>Cellular and Molecular Immunology</i> , <b>2021</b> , 18, 936-944	15.4 62
334	An interactive COVID-19 virus Mutation Tracker (CovMT) with a particular focus on critical mutations in the Receptor Binding Domain (RBD) region of the Spike protein.	
333	Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions. <b>2021</b> , 18, 1	35
332	A phytochemical-based medication search for the SARS-CoV-2 infection by molecular docking models towards spike glycoproteins and main proteases.. <b>2021</b> , 11, 12003-12014	10
331	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multi-epitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. <b>2021</b> , 10, 1931-1946	6
330	Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. <b>2021</b> , 12, 469	74
329	COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. <b>2021</b> , 40, 905-919	109
328	Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. <b>2021</b> , 19, 3799-3809	12
327	Binding affinity and mechanisms of SARS-CoV-2 variants. <b>2021</b> , 19, 4184-4191	5
326	Impact of meteorological parameters and population density on variants of SARS-CoV-2 and outcome of COVID-19 pandemic in Japan. <b>2021</b> , 149, e103	4
325	Dynamics and electrostatics define an allosteric druggable site within the receptor-binding domain of SARS-CoV-2 spike protein. <b>2021</b> , 595, 442-451	4
324	Protein-based lateral flow assays for COVID-19 detection. <b>2021</b> , 34,	12
323	Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. <b>2021</b> , 13,	30
322	COVID-19 vaccine: where are we now and where should we go?. <b>2021</b> , 20, 23-44	39

321	Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-CoV-2. <b>2021</b> , 26,	16
320	SARS-CoV-2 Worldwide Replication Drives Rapid Rise and Selection of Mutations across the Viral Genome: A Time-Course Study Potential Challenge for Vaccines and Therapies.	0
319	SARS-CoV-2 spike protein-, main protease- and papain-like-protease-targeting peptides from seed proteins following gastrointestinal digestion: An study.. <b>2021</b> , 1, 100016	7
318	Potential bioactive compounds of medicinal plants against new Coronavirus (SARS-CoV-2): A review. <b>2021</b> , 6, 1653-1658	2
317	SARS-CoV-2 variant evolution in the United States: High accumulation of viral mutations over time likely through serial Founder Events and mutational bursts.	1
316	Evolutionary analysis of SARS-CoV-2 spike protein for its different clades. <b>2021</b> , 93, 3000-3006	10
315	The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. <b>2021</b> , 10,	86
314	Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19. <b>2021</b> , 12, 1793-1802	33
313	Multispecific DARPins therapeutics demonstrate very high potency against SARS-CoV-2 variants in vitro.	4
312	VOC 202012/01 Variant Is Effectively Neutralized by Antibodies Produced by Patients Infected before Its Diffusion in Italy. <b>2021</b> , 13,	7
311	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. <b>2021</b> , 592, 283-289	223
310	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies : Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations.	1
309	Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals.	76
308	Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a fourplex real-time quantitative reverse transcription-PCR assays.	
307	A time series forecasting of the proportion of SARS-CoV-2 N501Y lineage in North America.	
306	Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers.	3
305	Exploring the role of glycans in the interaction of SARS-CoV-2 RBD and human receptor ACE2.	1
304	Critical interactions for SARS-CoV-2 spike protein binding to ACE2 identified by machine learning.	1

303	The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice.	62
302	Molecular detection of SARS-CoV-2 being challenged by virus variation and asymptomatic infection. <b>2021</b> , 11, 257-264	9
301	Impact of a new SARS-CoV-2 variant on the population: A mathematical modeling approach.	2
300	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2.	2
299	Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status. <b>2021</b> , 118, 102596	11
298	Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein. <b>2021</b> , 7, e06564	13
297	Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. <b>2021</b> , 31, e2231	64
296	Impact of a New SARS-CoV-2 Variant on the Population: A Mathematical Modeling Approach. <b>2021</b> , 26, 25	10
295	Covid-19: variants and vaccination. <b>2021</b> , 372, n771	26
294	The effect of spike mutations on SARS-CoV-2 neutralization. <b>2021</b> , 34, 108890	113
293	Perspectives and Challenges in the Fight Against COVID-19: The Role of Genetic Variability. <b>2021</b> , 11, 598875	6
292	The effects of novel coronavirus (SARS-CoV-2) infection on cardiovascular diseases and cardiopulmonary injuries. <b>2021</b> , 51, 102168	11
291	Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity. <b>2021</b> ,	1
290	Genomic Surveillance of Circulating SARS-CoV-2 in South East Italy: A One-Year Retrospective Genetic Study. <b>2021</b> , 13,	3
289	Host barriers to SARS-CoV-2 demonstrated by ferrets in a high-exposure domestic setting. <b>2021</b> , 118,	20
288	Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase. <b>2021</b> , 16, 881-895	2
287	Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveal Allosteric Duality of Functionally Adaptable Hotspots.	
286	In Silico Identification of Multi-target Anti-SARS-CoV-2 Peptides from Quinoa Seed Proteins. <b>2021</b> , 27, 1-11	6

285	Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies. <b>2021</b> , 125, 4596-4619	16
284	Relative Mutant N501Y SARS-CoV-2 Spike Protein RBD Inhibition of Anti-Spike Protein IgG and ACE-2 Binding to Spike Protein Species.	
283	Tackling Covid-19 using disordered-to-order transition of residues in the spike protein upon angiotensin-converting enzyme 2 binding. <b>2021</b> , 89, 1158-1166	5
282	Protein Footprinting, Conformational Dynamics, and Core Interface-Adjacent Neutralization "Hotspots" in the SARS-CoV-2 Spike Protein Receptor Binding Domain/Human ACE2 Interaction. <b>2021</b> , 32, 1593-1600	4
281	D936Y and Other Mutations in the Fusion Core of the SARS-CoV-2 Spike Protein Heptad Repeat 1: Frequency, Geographical Distribution, and Structural Effect. <b>2021</b> , 26,	11
280	ACE2 glycans preferentially interact with the RBD of SARS-CoV-2 over SARS-CoV.	
279	Silibinin as potential tool against SARS-Cov-2: In silico spike receptor-binding domain and main protease molecular docking analysis, and in vitro endothelial protective effects. <b>2021</b> , 35, 4616-4625	5
278	Antibodies and Vaccines Target RBD of SARS-CoV-2. <b>2021</b> , 8, 671633	32
277	Molecular Dynamic Simulation Search for Possible Amphiphilic Drug Discovery for Covid-19. <b>2021</b> , 26,	
276	Linking COVID-19 and Heme-Driven Pathophysiologies: A Combined Computational-Experimental Approach. <b>2021</b> , 11,	5
275	The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2. <b>2021</b> , 32, 1-8	5
274	Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures. <b>2021</b> , 177, 112969	6
273	Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality. <b>2021</b> ,	4
272	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. <b>2021</b> , 60, 1459-1484	17
271	Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation. <b>2021</b> , 12, 4059-4066	10
270	Role of Serine Proteases and Host Cell Receptors Involved in Proteolytic Activation, Entry of SARS-CoV-2 and Its Current Therapeutic Options. <b>2021</b> , 14, 1883-1892	5
269	Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection. <b>2021</b> ,	14
268	Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America. <b>2021</b> , 13,	7

267	Deamidation drives molecular aging of the SARS-CoV-2 spike receptor-binding motif.	
266	Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model. <b>2021</b> , 12, 641447	8
265	Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor. <b>2021</b> , 125, 5537-5548	15
264	Antiviral and Anti-Inflammatory Treatment with Multifunctional Alveolar Macrophage-Like Nanoparticles in a Surrogate Mouse Model of COVID-19. <b>2021</b> , 8, 2003556	4
263	SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test. <b>2021</b> , 51, e13573	4
262	Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2. <b>2021</b> , 13,	5
261	Development of a SARS-CoV-2-derived receptor-binding domain-based ACE2 biosensor. <b>2021</b> , 334, 129663	4
260	SARS-CoV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time-course study - potential challenge for vaccines and therapies. <b>2021</b> , 13, e14062	10
259	Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic.. <b>2021</b> , 1, 100027	4
258	In Silico Molecular-Based Rationale for SARS-CoV-2 Spike Circulating Mutations Able to Escape Bamlanivimab and Etesevimab Monoclonal Antibodies.	2
257	Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases. <b>2021</b> , 17, 2824-2840	3
256	CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants. <b>2021</b> , 21, 602	34
255	Immunolocalization studies of vimentin and ACE2 on the surface of cells exposed to SARS-CoV-2 Spike proteins.	1
254	A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus. <b>2021</b> , 2, 430	13
253	Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2. <b>2021</b> , 27, 206	6
252	Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro.	1
251	The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour.	3
250	Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. <b>2021</b> , 12, 658519	24

249	Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers. <b>2021</b> , 4, 109-122	2
248	Attractive and repulsive residue fragments at the interface of SARS-CoV-2 and hACE2. <b>2021</b> , 11, 12567	1
247	Coronavirus new variants: the mutations cause and the effect on the treatment and vaccination. <b>2021</b> , 2, 70-78	4
246	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. <b>2021</b> , 8, e2100985	8
245	A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro. <b>2021</b> , 13,	0
244	The bat ACE2 and multiple animal orthologs are functional receptors for bat coronavirus RaTG13 and SARS-CoV-2. <b>2021</b> , 66, 1215-1227	9
243	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <b>2021</b> , 12, 676314	5
242	V483A: an emerging mutation hotspot of SARS-CoV-2. <b>2021</b> ,	4
241	Middle East respiratory syndrome coronavirus Spike protein variants exhibit geographic differences in virulence. <b>2021</b> , 118,	3
240	Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study. <b>2021</b> , 28, 3262-3269	3
239	Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. <b>2021</b> , 54, 1290-1303.e7	35
238	Deep Mutational Scanning of Dynamic Interaction Networks in the SARS-CoV-2 Spike Protein Complexes: Allosteric Hotspots Control Functional Mimicry and Resilience to Mutational Escape.	
237	The landscape of antibody binding in SARS-CoV-2 infection. <b>2021</b> , 19, e3001265	17
236	Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots. <b>2021</b> , 17, 4578-4598	7
235	Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host. <b>2021</b> , 7, veab061	2
234	Machine Learning Reveals the Critical Interactions for SARS-CoV-2 Spike Protein Binding to ACE2. <b>2021</b> , 12, 5494-5502	14
233	Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. <b>2021</b> , 6, 226	34
232	First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020. <b>2021</b> , 21, e147	52



231	High resolution linear epitope mapping of the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 mRNA vaccine recipients.	
230	Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles. <b>2021</b> , 343, 109480	8
229	Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach. <b>2021</b> , 91, 104815	5
228	SARS-CoV-2 variant evolution in the United States: High accumulation of viral mutations over time likely through serial Founder Events and mutational bursts. <b>2021</b> , 16, e0255169	12
227	Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor-binding domain mutations: Receptor affinity versus neutralization of receptor interaction. <b>2021</b> ,	11
226	Atomistic Simulations and Deep Mutational Scanning of Protein Stability and Binding Interactions in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms.	
225	Non-RBM Mutations Impaired SARS-CoV-2 Spike Protein Regulated to the ACE2 Receptor Based on Molecular Dynamic Simulation. <b>2021</b> , 8, 614443	2
224	Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity. <b>2021</b> , 7, 1368-1380	5
223	Reduced neutralization of SARS-CoV-2 B.1.617 variant by inactivated and RBD-subunit vaccine.	1
222	Computational optimization of the SARS-CoV-2 receptor-binding-motif affinity for human ACE2. <b>2021</b> , 120, 2859-2871	7
221	Interference of Polydatin/Resveratrol in the ACE2:Spike Recognition during COVID-19 Infection. A Focus on Their Potential Mechanism of Action through Computational and Biochemical Assays. <b>2021</b> , 11,	12
220	Sequence similarity in 3D for comparison of protein families. <b>2021</b> , 106, 107906	0
219	Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants. <b>2021</b> , 7, 53	6
218	Emerging SARS-CoV-2 variants of concern and potential intervention approaches. <b>2021</b> , 25, 244	86
217	Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy.	1
216	Novel and emerging mutations of SARS-CoV-2: Biomedical implications. <b>2021</b> , 139, 111599	12
215	Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian Variant) From Predicted Spike Protein Structure. <b>2021</b> , 13, e16905	1
214	Altered interaction between RBD and ACE2 receptor contributes towards the increased transmissibility of SARS CoV-2 delta, kappa, beta, and gamma strains with RBD double mutations.	1

213	Molecular Dynamics Simulation Study of the Interaction between Human Angiotensin Converting Enzyme 2 and Spike Protein Receptor Binding Domain of the SARS-CoV-2 B.1.617 Variant. <b>2021</b> , 11,	3
212	Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency. <b>2021</b> , 11,	7
211	SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage.	8
210	The Emergence and Spread of Novel SARS-CoV-2 Variants. <b>2021</b> , 9, 696664	5
209	The Promise of Mutation Resistant Drugs for SARS-CoV-2 That Interdict in the Folding of the Spike Protein Receptor Binding Domain. <b>2021</b> , 1, 288-302	0
208	Expression pattern and function of SARS-CoV-2 Receptor ACE2. <b>2021</b> , 3, 312-312	1
207	Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen. <b>2021</b> , 12, 707977	6
206	Polyphenolic Natural Products Active In Silico against SARS-CoV-2 Spike Receptor Binding Domains and Non-Structural Proteins - A Review. <b>2021</b> ,	2
205	Characterization of Phytochemicals in L. and Their Action Against Spike Glycoprotein Receptor-Binding Domain. <b>2021</b> , 9, 735768	2
204	The SARS-CoV-2 spike protein is vulnerable to moderate electric fields. <b>2021</b> , 12, 5407	5
203	Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India). <b>2021</b> , 7, 100054	23
202	Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19.	0
201	Atomistic Simulations and In Silico Mutational Profiling of Protein Stability and Binding in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms. <b>2021</b> , 6, 26354-26371	2
200	Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin converting enzyme 2). <b>2021</b> , 1-12	5
199	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <b>2021</b> , 9,	23
198	The ubiquitous buried water in the beta-trefoil architecture contributes to the folding nucleus and ~20% of the folding enthalpy. <b>2021</b> , 30, 2287-2297	5
197	Allosteric Control of Structural Mimicry and Mutational Escape in the SARS-CoV-2 Spike Protein Complexes with the ACE2 Decoys and Miniprotein Inhibitors: A Network-Based Approach for Mutational Profiling of Binding and Signaling. <b>2021</b> , 61, 5172-5191	2
196	SARS-CoV-2 variants of concern infect the respiratory tract and induce inflammatory response in wild-type laboratory mice.	3

195	Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro. <b>2021</b> , 13,	7
194	Featuring ACE2 binding SARS-CoV and SARS-CoV-2 through a conserved evolutionary pattern of amino acid residues. <b>2021</b> , 1-10	1
193	A study protocol to prepare an RBD protein for vaccine against COVID-19. 10, 943	
192	Deamidation drives molecular aging of the SARS-CoV-2 spike protein receptor-binding motif. <b>2021</b> , 297, 101175	0
191	Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents. <b>2021</b> , 278, 114303	3
190	Discovery of Taroxaz-104: The first potent antidote of SARS-CoV-2 VOC-202012/01 strain. <b>2021</b> , 1246, 131106	7
189	Contact residue contributions to interaction energies between SARS-CoV-1 spike proteins and human ACE2 receptors. <b>2021</b> , 11, 1156	3
188	ACE2 glycans preferentially interact with SARS-CoV-2 over SARS-CoV. <b>2021</b> , 57, 5949-5952	6
187	The impact of Spike mutations on SARS-CoV-2 neutralization.	22
186	Unbuttoning the impact of N501Y mutant RBD on viral entry mechanism: A computational insight.	1
185	Label-free methods for optical characterization of protein-protein interactions. <b>2021</b> , 23, 16488-16500	3
184	COVID-19 and autoimmune diseases. <b>2021</b> , 33, 155-162	119
183	D936Y and Other Mutations in the Fusion Core of the SARS-Cov-2 Spike Protein Heptad Repeat 1 Undermine the Post-Fusion Assembly.	8
182	The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. <b>2020</b> ,	62
181	Novel surrogate virus neutralization test reveals low serum neutralizing anti-SARS-CoV-2-S antibodies levels in mildly affected COVID-19 convalescents.	5
180	Neutralization Assay with SARS-CoV-1 and SARS-CoV-2 Spike Pseudotyped Murine Leukemia Virions. <b>2020</b> ,	4
179	Computational optimization of the SARS-CoV-2 receptor-binding-motif affinity for human ACE2.	2
178	Peptide Antidotes to SARS-CoV-2 (COVID-19).	8

177	Ferrets not infected by SARS-CoV-2 in a high-exposure domestic setting.	8
176	A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates.	61
175	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. <b>2020</b> ,	2
174	Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor.	7
173	Clade GR and Clade GH Isolates in Asia Show Highest Amount of SNPs.	1
172	BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2.	6
171	Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa.	446
170	Pharmacophore-based peptide biologics neutralize SARS-CoV-2 S1 and deter S1-ACE2 interaction in vitro.	1
169	Footprint of the COVID-19 Pandemic in India: A Study of Immune Landscape and Other Factors Shielding Mortality. <b>2020</b> , 2020, 6692739	1
168	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. <b>2020</b> , 16, e1009089	33
167	Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2. <b>2020</b> ,	8
166	Identification of Putative Cell-entry-inhibitory Peptides against SARS-CoV-2 from Edible Insects: An in silico Study. <b>2020</b> , 1, 357	9
165	Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. <b>2021</b> , 13, 164	10
164	Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. <b>2021</b> , 1868, 166294	6
163	Imaging and visualizing SARS-CoV-2 in a new era for structural biology.. <b>2021</b> , 11, 20210019	1
162	Expression and characterization of SARS-CoV-2 spike proteins. <b>2021</b> , 16, 5339-5356	4
161	Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. <b>2021</b> , 11, 20274	8
160	Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro. <b>2021</b> , 35, e21970	4

- 159 Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection. **2021**, 2
- 158 A bacteria-based assay to study SARS-CoV-2 protein-protein interactions.
- 157 SS3D: Sequence similarity in 3D for comparison of protein families.
- 156 An Ultrasensitive Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and in vitro. 0
- 155 Computaci3n heterog3nea de alta performance: aplicaci3n en el dise1o racional de f1rmacos. **2020**,
- 154 Complex Pathophysiological Mechanisms and the Propose of the Three-Dimensional Schedule For Future COVID-19 Treatment. **2021**, 12, 716940
- 153 An Intranasal Vaccine Based on Outer Membrane Vesicles Against SARS-CoV-2. **2021**, 12, 752739 7
- 152 Transmission dynamics, clinical characteristics and sero-surveillance in the COVID-19 outbreak in a population dense area of Colombo, Sri Lanka April- May 2020. **2021**, 16, e0257548 1
- 151 The Rhinolophus affinis bat ACE2 and multiple animal orthologs are functional receptors for bat coronavirus RaTG13 and SARS-CoV-2.
- 150 Evolutionary analysis of SARS-CoV-2 spike protein for its different clades. 0
- 149 [Immunity against SARS-CoV-2: walking to the vaccination]. **2020**, 33, 392-398 1
- 148 Treatment and prognosis of COVID-19: Current scenario and prospects (Review). **2021**, 21, 3 3
- 147 A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display.. **2021**, 9, 1
- 146 A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions. **2021**, e0293621 0
- 145 Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19. **2021**, 44,
- 144 Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. **2021**, 13, 3
- 143 Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine candidate based on a novel recombinant RBD fusion heterodimer of SARS-CoV-2. 1
- 142 Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural COVID-19 infections over a three-month period. **2021**, 4

141	A Comparative Study between Spanish and British SARS-CoV-2 Variants. <b>2021</b> , 43, 2036-2047	
140	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <b>2021</b> , 101533	11
139	Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. <b>2021</b> , 16, e0260283	
138	In Silico Analysis of Bacteriocins from Lactic Acid Bacteria Against SARS-CoV-2. <b>2021</b> , 1	1
137	High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. <b>2021</b> , e0096521	2
136	A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies. <b>2021</b> , 1,	1
135	Penta-peptide ATN-161 based neutralization mechanism of SARS-CoV-2 spike protein. <b>2021</b> , 28, 101170	3
134	Coronavirus (SARS-CoV-2) causes lung inflammation and injury. <b>2021</b> ,	2
133	Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera. <b>2021</b> ,	2
132	A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models.. <b>2022</b> ,	5
131	Structural and functional insights into the major mutations of SARS-CoV-2 Spike RBD and its interaction with human ACE2 receptor.. <b>2021</b> , 101773	2
130	Treatment and prognosis of COVID-19: Current scenario and prospects (Review). <b>2020</b> , 20, 1-1	9
129	Predictive Profiling of SARS-CoV-2 Variants by Deep Mutational Learning.	
128	Impact of ADAR-induced editing of minor viral RNA populations on replication and transmission of SARS-CoV-2.. <b>2022</b> , 119,	4
127	The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour.. <b>2021</b> ,	2
126	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission.. <b>2022</b> ,	23
125	Review of Clinical Performance of Serology Based Commercial Diagnostic Assays for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies.. <b>2022</b> ,	0
124	Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its first variants in fourplex real-time quantitative reverse transcription-PCR assays.. <b>2022</b> , 9, 1-20	0

123	Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.. <b>2022,</b>	12
122	Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants.. <b>2022, 14, 2021601</b>	1
121	Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction.. <b>2022, 23, 2</b>	4
120	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.. <b>2022, 29, 1</b>	17
119	Establishment of a Rapid Typing Method for Coronavirus Disease 2019 Mutant Strains Based on PARMS Technology.. <b>2022, 13,</b>	
118	Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift.. <b>2022,</b>	2
117	Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.. <b>2022, 14,</b>	2
116	Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor.. <b>2021, 590, 34-41</b>	39
115	Phylogenetic analysis of SARS-CoV-2 viruses circulating in the South American region: Genetic relations and vaccine strain match.. <b>2022, 311, 198688</b>	0
114	Molecular Dynamics Simulations Studies On The Effects Of Mutations On The Binding Affinities Between SARS-CoV-2 Spike RBD And Human ACE2.	
113	Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2.. <b>2022, 1</b>	2
112	Molecular markers for early stratification of disease severity and progression in COVID-19.	
111	Are There Hidden Genes in DNA/RNA Vaccines?. <b>2022, 13, 801915</b>	1
110	Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor.	1
109	The Molecular Virology of Coronaviruses with Special Reference to SARS-CoV-2.. <b>2021, 1352, 15-31</b>	1
108	Intrinsically Disordered Proteins: Perspective on COVID-19 Infection and Drug Discovery.. <b>2022,</b>	4
107	Coronavirus and Carbon Nanotubes: Seeking Immunological Relationships to Discover Immunotherapeutic Possibilities.. <b>2022, 17, 751-781</b>	2
106	Correlation of SARS-CoV-2 to cancer: Carcinogenic or anticancer? (Review).. <b>2022, 60,</b>	0

105	Phage Display-Derived Compounds Displace hACE2 from Its Complex with SARS-CoV-2 Spike Protein.. <b>2022</b> , 10,	0
104	E-Volve: understanding the impact of mutations in SARS-CoV-2 variants spike protein on antibodies and ACE2 affinity through patterns of chemical interactions at protein interfaces.. <b>2022</b> , 10, e13099	
103	A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions.. <b>2022</b> , 119, e2114397119	0
102	A CNN model for predicting binding affinity changes between SARS-CoV-2 spike RBD variants and ACE2 homologues.. <b>2022</b> ,	
101	An Overview of SARS-CoV-2 Molecular Diagnostics in Europe. <b>2022</b> ,	0
100	Spike protein of SARS-CoV-2 variants: a brief review and practical implications.. <b>2022</b> , 1	1
99	Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design.. <b>2022</b> , e2347	1
98	Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.. <b>2022</b> , 200, 105290	1
97	Systematic profiling of antigen bias in humoral response against SARS-CoV-2.. <b>2022</b> , 198711	
96	Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study. 11, 400	
95	Messenger Ribonucleic Acid Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2 - A Review.. <b>2021</b> ,	1
94	Soluble Human Angiotensin- Converting Enzyme 2 as a Potential Therapeutic Tool for COVID-19 is Produced at High Levels In Plant With Potent Anti-SARS-CoV-2 Activity.. <b>2021</b> , 12, 742875	2
93	SARS-CoV-2 Variants of Concern Infect the Respiratory Tract and Induce Inflammatory Response in Wild-Type Laboratory Mice.. <b>2021</b> , 14,	4
92	Predictive profiling of SARS-CoV-2 variants by deep mutational learning.	0
91	RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor.. <b>2021</b> , 14,	2
90	SARS-CoV-2 Variant Screening Using a Virus-Receptor-Based Electrical Biosensor.. <b>2021</b> ,	3
89	A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues.. <b>2022</b> ,	0
88	Amomum tsao-ko essential oil, a Novel Anti-COVID-19 Omircon Spike Protein Natural Products: A Computational Study.. <b>2022</b> , 103916	0



87	Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains.. <b>2022</b> , 14,	2
86	Subtyping of major SARS-CoV-2 variants reveals different transmission dynamics.	0
85	Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems.. <b>2022</b> , 14,	0
84	Repurposing of Four Drugs as Anti-SARS-CoV-2 Agents and Their Interactions with Protein Targets. <b>2022</b> , 90, 24	1
83	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment.. <b>2022</b> ,	0
82	Nano-size Dependent Protein Corona Formation by SARS-CoV-2 Omicron Spike Protein Over Gold Nano-Colloid and Reversible Aggregation.. <b>2022</b> , 128967	0
81	Table_1.pdf. <b>2020</b> ,	
80	Table_1.DOCX. <b>2020</b> ,	
79	Table_2.XLSX. <b>2020</b> ,	
78	SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses.. <b>2022</b> , 20, 2042-2056	0
77	Covid-19: virology, variants, and vaccines. <b>2022</b> , 1, e000040	0
76	Cell surface detection of vimentin, ACE2 and SARS-CoV-2 Spike proteins reveals selective colocalization at primary cilia.. <b>2022</b> , 12, 7063	1
75	Comprehensive Role of SARS-CoV-2 Spike Glycoprotein in Regulating Host Signaling Pathway.. <b>2022</b> ,	0
74	Adsorption of Pulmonary and Exogeneous Surfactants on SARS-CoV-2 Spike Protein.. <b>2022</b> ,	
73	Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants.. <b>2022</b> , 14, 2072455	0
72	Antiviral Drug Discovery for the Treatment of COVID-19 Infections. <b>2022</b> , 14, 961	3
71	The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. <b>2022</b> , 9,	0
70	nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. 1	

69	Novel Targets of SARS-CoV-2 and Potential Inhibitors against the Viral Targeted Proteins: A Review. <b>2022</b> , 34, 1354-1360	
68	Discovery of Natural Lead Compound from <i>Dendrobium</i> sp. against SARS-CoV-2 Infection. <b>2022</b> , 15, 620	1
67	Exploring the Spike-hACE 2 Residue-Residue Interaction in Human Coronaviruses SARS-CoV-2, SARS-CoV, and HCoV-NL63.	0
66	Animal models for studying coronavirus infections and developing antiviral agents and vaccines. <b>2022</b> , 203, 105345	1
65	Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants.	0
64	Rise of the SARS-CoV-2 Variants: Can proteomics be the silver bullet?.	0
63	Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy. <b>2022</b> , 29,	
62	Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees. <b>2022</b> , 13,	3
61	Analysis of Whole-Genome Sequencing of SARS-CoV-2 Reveals Recurrent Mutations among Iranian Patients.	
60	Jigsaw puzzle of SARS-CoV-2 RBD evolution and immune escape.	0
59	Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. <b>2022</b> , 7, 1063-1074	4
58	COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants. <b>2022</b> , 28,	0
57	Human ACE2 Genetic Polymorphism Affecting SARS-CoV and SARS-CoV-2 Entry into Cells.	0
56	The trispesific DARPIn ensovibep inhibits diverse SARS-CoV-2 variants. <i>Nature Biotechnology</i> ,	44.5 1
55	The First Geographic Identification by Country of Sustainable Mutations of SARS-COV2 Sequence Samples: Worldwide Natural Selection Trends.	0
54	Correlation between In Vitro Neutralization Assay and Serological Tests for Protective Antibodies Detection. <b>2022</b> , 23, 9566	3
53	Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution. <b>2022</b> , 78,	0
52	mRNA vaccines and hybrid immunity use different B cell germlines to neutralize Omicron BA.4 and BA.5.	2

51	Evolution of Stronger SARS-CoV-2 Variants as Revealed Through the Lens of Molecular Dynamics Simulations.	
50	Computational Design of Miniprotein Inhibitors Targeting SARS-CoV-2 Spike Protein.	1
49	Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019–2022. <b>2022</b> , 17, e0271074	3
48	Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of infection, transmission, immune escape, and mutational landscape.	2
47	A study protocol to prepare an RBD protein for vaccine against COVID-19. 10, 943	
46	Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening. <b>2022</b> , 321, 198915	0
45	Antibody-mediated immunity to SARS-CoV-2 spike. <b>2022</b> , 1-69	0
44	Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. <b>2022</b> ,	3
43	SARS-CoV-2 Spatiotemporal Genomic and Molecular Analysis of the First Wave of the COVID-19 Pandemic in Macaé—the Brazilian Capital of Oil. <b>2022</b> , 23, 11497	0
42	A study protocol to prepare an RBD protein for vaccine against COVID-19. 10, 943	0
41	Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein. <b>2022</b> , 23, 10315	0
40	A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets.	0
39	A comparative study of receptor interactions between SARS-CoV and SARS-CoV-2 from molecular modeling. <b>2022</b> , 28,	0
38	Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies. 9,	1
37	SARS-CoV-2 vaccines: A double-edged sword throughout rapid evolution of COVID-19.	0
36	Subtyping of major SARS-CoV-2 variants reveals different transmission dynamics based on 10 million genomes.	0
35	Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan- $\beta$ -coronavirus vaccines.	1
34	Biological effect of black phosphorus nanosheets to the interaction between SARS-CoV-2 S protein and ACE2.	0

- 33 Cell Entry and Unusual Replication of SARS-CoV2. **2022**, 24, ○
- 32 Proteomic Approach for Comparative Analysis of the Spike Protein of SARS-CoV-2 Omicron (B.1.1.529) Variant and Other Pango Lineages. **2022**, 10, 34 ○
- 31 Cyclophilin A-mediated mitigation of coronavirus SARS-CoV -2. 1
- 30 Molecular markers for early stratification of disease severity and progression in COVID-19. ○
- 29 Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation. **2022**, 110244 ○
- 28 Gender and age features of the formation of a humoral immune response to COVID-19 vaccination. **2022**, 11, 17 ○
- 27 Infrared spectra of the SARS-CoV-2 spike receptor-binding domain: Molecular dynamics simulations. **2022**, 140176 ○
- 26 Automated detection of neutralizing SARS-CoV-2 antibodies in minutes using a competitive chemiluminescence immunoassay. ○
- 25 Evaluation of panel of neutralising murine monoclonal antibodies and a humanised bispecific antibody against influenza A(H1N1)pdm09 virus infection in a mouse model. **2022**, 208, 105462 ○
- 24 DAPTEV: Deep aptamer evolutionary modelling for COVID-19 drug design. ○
- 23 The Role of Host Cell Glycans on Virus Infectivity: The SARS-CoV-2 Case. 2201853 ○
- 22 SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy. **2022**, 12, 1742 1
- 21 Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. **2022**, 50, 1643-1658 ○
- 20 Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel 85 Protects K18-hACE2 Mice against Lethal Virus Challenge. **2022**, 10, 2119 ○
- 19 Pharmacoinformatic approach to identify potential phytochemicals against SARS-CoV-2 spike receptor-binding domain in native and variants of concern. ○
- 18 Omicron SARS-CoV-2 Variants in an In Silico Genomic Comparison Study with the Original Wuhan Strain and WHO-Recognized Variants of Concern. **2022**, 71, 577-587 ○
- 17 Genomic landscape of alpha-variant of SARS-CoV-2 circulated in Pakistan. **2022**, 17, e0276171 ○
- 16 Design of a multi-epitope-based vaccine consisted of immunodominant epitopes of structural proteins of SARS-CoV-2 using immunoinformatics approach. ○

- 15 QM/MM study of N501 involved intermolecular interaction between SARS-CoV-2 receptor binding domain and antibody of human origin. **2023**, 102, 107810
- 14 Computational Analysis of Receptor-Binding Domains of SARS-CoV-2 to Reveal the Mechanism of Immune Escape. **2022**,
- 13 Assessment of the Prevalence and Incidence of COVID-19 in Saudi Arabia. Volume 16, 227-236
- 12 Lipid-Based Poly(I:C) Adjuvants Strongly Enhance the Immunogenicity of SARS-CoV-2 Receptor-Binding Domain Vaccine. **2023**, 3, 3-12
- 11 Mechanisms of SARS-CoV-2 Inactivation using UVC Laser Radiation.
- 10 Antibody isotype epitope mapping of SARS-CoV-2 Spike RBD protein: Targets for COVID-19 symptomatology and disease control. **2023**, 53,
- 9 Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2. **2023**, 26, 106126
- 8 Experimental and clinical data analysis for identification of COVID-19 resistant ACE2 mutations. **2023**, 13,
- 7 COVID-19: Prevention, Detection, and Treatment by Using Carbon Nanotubes-Based Materials. **2023**, 8,
- 6 In silico analysis of dietary polyphenols and their gut microbial metabolites suggest inhibition of SARS-CoV-2 infection, replication, and host inflammatory mediators. 1-19
- 5 No indication for SARS-CoV-2 transmission to pet ferrets, in five cities in Poland, 2021 - antibody testing among ferrets living with owners infected with SARS-CoV-2 or free of infection. **2023**, 65,
- 4 COVID-19 adenoviral vector vaccination elicits a robust memory B cell response with the capacity to recognize Omicron BA.2 and BA.5 variants.
- 3 Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein. **2023**, 21, 2339-2351
- 2 mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 and BA.5. **2023**, 14,
- 1 A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets. **2023**, 168,